• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc. (Amendment)

    2/14/24 4:19:04 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FULC alert in real time by email
    SC 13G/A 1 d752730dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Fulcrum Therapeutics, Inc.

    (Name of Issuer)

    COMMON STOCK, $0.001 PAR VALUE PER SHARE

    (Title of Class of Securities)

    359616109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 359616109    SCHEDULE 13G    Page 2 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures III, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    The percent of class was calculated based on 61,822,554 shares of common stock issued and outstanding as of October 31, 2023 as disclosed in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 7,2023.


    CUSIP No. 359616109    SCHEDULE 13G    Page 3 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures GP III, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 359616109    SCHEDULE 13G    Page 4 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TRV GP III, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO


    CUSIP No. 359616109    SCHEDULE 13G    Page 5 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures IV, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,343,154

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,343,154

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,343,154

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 359616109    SCHEDULE 13G    Page 6 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Third Rock Ventures GP IV, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,343,154

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,343,154

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,343,154

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 359616109    SCHEDULE 13G    Page 7 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TRV GP IV, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     2,343,154

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     2,343,154

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     2,343,154

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.8% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO


    CUSIP No. 359616109    SCHEDULE 13G    Page 8 of 13 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Robert I. Tepper

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     156,189

       6.   

     SHARED VOTING POWER

     

     0

       7.   

     SOLE DISPOSITIVE POWER

     

     156,189

       8.   

     SHARED DISPOSITIVE POWER

     

     0

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     156,189

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0.3% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     IN


    CUSIP No. 359616109    SCHEDULE 13G    Page 9 of 13 Pages

     

    Item 1.

    Issuer

     

      (a)

    Name of Issuer:

    Fulcrum Therapeutics, Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    26 Landsdowne Street

    Cambridge, MA 02139

     

    Item 2.

    Filing Person

     

      (a) – (c)

    Name of Persons Filing; Address; Citizenship:

     

      (i)

    Third Rock Ventures III, L.P. (“TRV III”);

     

      (ii)

    Third Rock Ventures GP III, L.P. (“TRV GP III”), which is the sole general partner of TRV III;

     

      (iii)

    TRV GP III, LLC (“TRV GP III LLC”), which is the sole general partner of TRV GP III;

     

      (iv)

    Third Rock Ventures IV, L.P. (“TRV IV”);

     

      (v)

    Third Rock Ventures GP IV, L.P. (“TRV GP IV”), which is the sole general partner of TRV IV;

     

      (vi)

    TRV GP IV, LLC (“TRV GP IV LLC”), which is the sole general partner of TRV GP IV; and

     

      (vii)

    Robert I. Tepper (“Tepper,” and collectively with TRV III, TRV GP III, TRV GP III LLC, TRV IV, TRV GP IV and TRV GP IV LLC, the “Reporting Persons”), the managing member of TRV GP III LLC.

    The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 201 Brookline Ave, Suite 1401, Boston, MA 02215.

    Each of TRV III, TRV GP III, TRV IV and TRV GP IV is a Delaware limited partnership. Each of TRV GP III LLC and TRV GP IV LLC is a Delaware limited liability company. Tepper is a United States citizen.

     

      (d)

    Title of Class of Securities:

    Common stock, $0.001 par value per share, (the “Common Stock”)

     

      (e)

    CUSIP Number:

    359616109

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;


    CUSIP No. 359616109    SCHEDULE 13G    Page 10 of 13 Pages

     

    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
       If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership.

    (a) and (b) Amount beneficially owned:

     

      (i)

    TRV III directly owns 0 shares of Common Stock (the “III Shares”), which represents 0% of the outstanding shares of Common Stock.

     

      (ii)

    TRV GP III is the general partner of TRV III and may be deemed to beneficially own any shares of Common Stock held by TRV III (if any).

     

      (iii)

    TRV GP III LLC is the general partner of TRV GP III and may be deemed to beneficially own any shares of Common Stock held by TRV III (if any).

     

      (iv)

    TRV IV directly owns 2,343,154 shares of Common Stock (the “Shares”), which represents approximately 3.8% of the outstanding shares of Common Stock.

     

      (v)

    TRV GP IV is the general partner of TRV IV and may be deemed to beneficially own the Shares.

     

      (vi)

    TRV GP IV LLC is the general partner of TRV GP IV and may be deemed to beneficially own the Shares.

     

      (vii)

    As the managing member of TRV GP III LLC Tepper may be deemed to beneficially own any shares of Common Stock held by TRV III (if any). Additionally, Tepper directly owns 156,189 shares of Common Stock, which represents approximately 0.3% of the outstanding shares of Common Stock.

     

      (c)

    Number of shares as to which such person has:

     

         Number of Shares of Common Stock  
    Reporting Person    (i)      (ii)      (iii)      (iv)  

    TRV III

         0        0        0        0  

    TRV GP III

         0        0        0        0  

    TRV GP III LLC

         0        0        0        0  

    TRV IV

         0        2,343,154        0        2,343,154  

    TRV GP IV

         0        2,343,154        0        2,343,154  

    TRV GP IV LLC

         0        2,343,154        0        2,343,154  

    Tepper

         156,189        0        156,189        0  


    CUSIP No. 359616109    SCHEDULE 13G    Page 11 of 13 Pages

     

      (i)

    Sole power to vote or direct the vote

     

      (ii)

    Shared power to vote or to direct the vote

     

      (iii)

    Sole power to dispose or to direct the disposition of

     

      (iv)

    Shared power to dispose or to direct the disposition of

    The percent of class was calculated based on 61,822,554 shares of common stock issued and outstanding as of October 31, 2023 as disclosed in the Issuer’s 10-Q filed with the Securities and Exchange Commission on November 7, 2023.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    CUSIP No. 359616109    SCHEDULE 13G    Page 12 of 13 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    THIRD ROCK VENTURES III, L.P.
    By: THIRD ROCK VENTURES GP III, L.P.,
    General Partner
    By: TRV GP III, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    THIRD ROCK VENTURES GP III, L.P.
    By: TRV GP III, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    TRV GP III, LLC
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    THIRD ROCK VENTURES IV, L.P.
    By: THIRD ROCK VENTURES GP IV, L.P.,
    General Partner
    By: TRV GP IV, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer


    CUSIP No. 359616109    SCHEDULE 13G    Page 13 of 13 Pages

     

    THIRD ROCK VENTURES GP IV, L.P.
    By: TRV GP IV, LLC,
    General Partner
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    TRV GP IV, LLC
    By:  

    /s/ Kevin Gillis

    Kevin Gillis
    Chief Operating Officer
    ROBERT I. TEPPER

    /s/ Kevin Gillis, As attorney-in-fact

    Robert I. Tepper
    Get the next $FULC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FULC

    DatePrice TargetRatingAnalyst
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    9/12/2024$4.00Outperform → Market Perform
    Leerink Partners
    9/12/2024$10.00 → $2.00Neutral → Underperform
    BofA Securities
    9/12/2024Buy → Hold
    Stifel
    More analyst ratings

    $FULC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employees an aggregate of 36,400

    8/8/25 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

    ― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan-cellular increases in fetal hemoglobin (HbF); meaningful improvements in key markers of hemolysis and anemia; encouraging trends in vaso-occlusive crises (VOCs) ― ― On track to provide clinical data from the 20 mg dose cohort by the end of 2025 ― ― Ended Q2 2025 with $214.1 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., July 29, 2025 (GLOBE NEWSWI

    7/29/25 6:48:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment

    7/29/25 6:45:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    3/5/24 4:15:17 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fulcrum Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously

    7/29/25 11:36:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Fulcrum Therapeutics from Market Perform to Outperform and set a new price target of $12.00

    5/23/25 8:13:14 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Fulcrum Therapeutics from Neutral to Overweight and set a new price target of $10.00

    5/15/25 8:05:44 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hill Colin

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    6/30/25 4:15:09 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ezekowitz Alan

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    6/30/25 4:15:04 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Haviland Kate

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    6/30/25 4:15:14 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

    SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    8/12/25 9:01:04 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Fulcrum Therapeutics Inc.

    10-Q - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    7/29/25 8:39:01 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Fulcrum Therapeutics, Inc. (0001680581) (Filer)

    7/29/25 8:34:24 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Leadership Updates

    Live Leadership Updates

    View All

    Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    8/19/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum's executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as

    3/18/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Appoints Chief Financial Officer

    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Alan A. Musso as chief financial officer, effective August 7, 2023. A 30-year veteran in the life sciences industry, Mr. Musso has held numerous financial and operational leadership positions over the course of his career. "We are delighted to welcome Alan to our executive leadership team," said Alex C. Sapir, president and chief executive officer at Fulcrum Therapeutics. "Alan's wealth of industry experience and impressive track record

    8/3/23 6:55:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/12/24 3:51:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FULC
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an increase in F-cells (red blood cells containing HbF) from a mean of 34% at baseline to 67% at 12 weeks of treatment ― ― Meaningful improvements in key markers of hemolysis coupled with a 0.9 g/dL mean increase in total hemoglobin (Hb) ― ― Encouraging trends in vaso-occlusive crisis (VOC) reduction compared to baseline ― ― Pociredir continued to be generally well-tolerated with no treatment-related serious adverse events (SAEs); all treatment

    7/29/25 6:45:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, July 29, 2025 beginning at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Sheinei Alan, Director of the Inova Fairfax Adult Sickle Cell Program, and Assistant Professor at UVA School of Medicine Inova Campus, and Dr. Wally Smith, Director at the VC

    7/28/25 4:01:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

    ― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the end of 2025 ― ― Ended Q1 2025 with $226.6 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improv

    5/1/25 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care